Status:
COMPLETED
A Cross-sectional Study of COPD and Symptom Variability in MEA Countries
Lead Sponsor:
AstraZeneca
Conditions:
Chronic Obstructive Pulmonary Disease
Eligibility:
All Genders
Brief Summary
This non-interventional study aims at assessing stable GOLD C and D COPD patient's perception of daily and weekly symptoms variability and their impact on daily activities. It will also explore the c...
Detailed Description
1. Primary objective: To assess perception of daily and weekly variability of symptoms in stable GOLD C and D COPD patients and their impact on daily life activities 2. Secondary objectives: * To ...
Eligibility Criteria
Inclusion
- Patients eligible for inclusion have to fulfill all of the following criteria:
- Stable GOLD C or D COPD patient under maintenance treatment, over 45 years, who provided signed informed consent;
- COPD diagnosis documented by spirometry performed in the past 12 months with an FEV1/FVC \< 0.7 and an FEV1 \< 50% predicted.
Exclusion
- Patients are not eligible for inclusion if they meet one of the following criteria:
- Patient with an ongoing COPD exacerbation\*;
- Patient who has experienced an exacerbation\* in the previous 3 months;
- History of asthma, allergic rhinitis, lung cancer or any other significant respiratory disease, such as tuberculosis, lung fibrosis or sarcoidosis;
- Inability to understand the study related questions;
- Mentally disabled patient or unable to read and write;
- Pregnant.
- Current participation in a clinical trial;
Key Trial Info
Start Date :
December 7 2015
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 31 2017
Estimated Enrollment :
3254 Patients enrolled
Trial Details
Trial ID
NCT03425760
Start Date
December 7 2015
End Date
March 31 2017
Last Update
June 29 2018
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.